EUVIMEDEUVIMED entdecken
Crossref

Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure – Data from the German Hepatitis C-Registry (DHC-R)

Valerie Ohlendorf, Yvonne Serfert, Peter Buggisch, Stefan Mauss, Hartwig Klinker, Gerlinde Teuber, Markus Cornberg, Krzysztof Tomasiewicz, Heiner Wedemeyer

Zeitschrift für Gastroenterologie · 01.05.2025 · 63 (05) · 486-496

DOI: 10.1055/a-2543-5205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.05.2025. Verfasst von Valerie Ohlendorf und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Chronic, Registries, Carcinoma, Hepatocellular. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infection are endowed with sustained virological response (SVR) rates >95%. However, HCV cure does not completely eliminate the risk of hepatocellular carcinoma (HCC) development and liver decompensation. The present study investigated the impact of the administered DAA regimen on clinical long-time outcomes after SVR. Matched-pair survival analyses of 5802 chronically HCV infected patients from the German Hepatitis C-Registry compared the incidence of liver-related events 2.5 years after SVR in patients receiving either sofosbuvir (SOF)-based treatment or NS3/NS4A-protease inhibitor (PI)-containing DAA regimens. Hypothesis driven logistic regression analyses were performed to identify independent predictors for the occurrence of liver-related events. Matched-pair survival analyses revealed a borderline significant difference in the incidence of liver-related endpoints (except of HCC development) in patients receiving SOF-based treatment (4.1%) compared to PI-containing DAA regimens (2.6%) 2.5 years after SVR (p=0.061). Numerically, a trend towards a benefit of PI-based DAA treatment was observed (PI 65 events vs SOF 102 events). Hypothesis driven logistic regression analyses could not confirm SOF-based treatment as an independent predictor for the occurrence of liver-related events after HCV cure (p=0.072, OR=0.670). The incidence of liver-related events 2.5 years after HCV cure did not differ significantly between SOF-based DAA treatment and PI-containing regimens. However, numerically a trend towards a benefit of PI-based DAA treatment was observed. Therefore, a minor effect of the applied DAA regimen on the long-term incidence of liver-related events cannot be excluded.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis C, ChronicRegistriesCarcinoma, HepatocellularLiver NeoplasmsHumansMaleGermanyFemaleMiddle AgedTreatment OutcomeAgedIncidenceSustained Virologic ResponseSurvival RateRisk FactorsAdultSofosbuvirDrug Therapy, Combination

Substanzen

Antiviral AgentsSofosbuvir

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Leberstiftungs-GmbH Deutschland, Hannover, Germany.
  • ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany.
  • Center for HIV and Hepatogastroenterology, Duesseldorf, Germany.
  • Division of Infectious Diseases, Department of Internal Medicine II, University of Würzburg Medical Center, Würzburg, Germany.
  • Practice PD Dr. med. G. Teuber, Frankfurt am Main, Germany.

Zitieren

APA

Ohlendorf, V., Serfert, Y., Buggisch, P., Mauss, S., Klinker, H., Teuber, G., Cornberg, M., Tomasiewicz, K., & Wedemeyer, H. (2025). Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure – Data from the German Hepatitis C-Registry (DHC-R). Zeitschrift für Gastroenterologie, 63(05), 486-496. https://doi.org/10.1055/a-2543-5205

Vancouver

Ohlendorf V, Serfert Y, Buggisch P, Mauss S, Klinker H, Teuber G, et al. Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure – Data from the German Hepatitis C-Registry (DHC-R). Zeitschrift für Gastroenterologie. 2025;63(05):486-496. doi:10.1055/a-2543-5205

BibTeX
@article{Ohlendorf2025,
  author = {Ohlendorf, Valerie and Serfert, Yvonne and Buggisch, Peter and Mauss, Stefan and Klinker, Hartwig and Teuber, Gerlinde and Cornberg, Markus and Tomasiewicz, Krzysztof and Wedemeyer, Heiner},
  title = {Impact of distinct antiviral treatment regimens on the long-term outcome after HCV cure – Data from the German Hepatitis C-Registry (DHC-R)},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2025},
  volume = {63},
  number = {05},
  pages = {486--496},
  doi = {10.1055/a-2543-5205}
}
Kostenlos starten →